Viskase Holdings, Inc.

VISK ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-3.4M $778.0K $1.4M $-186.0K $-469.0K $-1.3M $-979.0K $5.8M
Depreciation & Amortization — — — — — — — —
Depreciation — — — — — — — —
Amortization — — — — — — — —
Stock-Based Compensation — — — — — — — —
Net Cash from Operating Activities $-3.0M $1.1M $1.3M $-659.0K $-501.0K $-380.0K $6.9M $-978.0K
Investing Activities
Capital Expenditures — — — — — — — —
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities — — — — — — — —
Financing Activities
Dividends Paid $1.3M $1.3M $1.3M — $0 $0 $8.0M $0
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $-1.3M $-1.3M $-1.3M — $0 $43.1M $-8.0M $0
Net Change in Cash $-4.3M $-153.0K $30.0K $-659.0K $-501.0K $42.7M $-1.1M $-978.0K
Free Cash Flow — — — — — — — —
← Newer Page 1 of 3 Older →